197 825

Cited 32 times in

Lymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy.

DC Field Value Language
dc.contributor.author김수정-
dc.contributor.author정준원-
dc.contributor.author김유리-
dc.contributor.author김진석-
dc.contributor.author민유홍-
dc.date.accessioned2014-12-20T16:59:24Z-
dc.date.available2014-12-20T16:59:24Z-
dc.date.issued2011-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/93760-
dc.description.abstractBACKGROUND: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) is a heterogeneous group of aggressive T-cell lymphomas with poor treatment outcomes. The aim of this study was to evaluate whether lymphopenia at diagnosis would have an adverse effect on survival in patients with PTCL-NOS treated with anthracycline-containing chemotherapy. METHODS: A total of 118 patients with PTCL-NOS treated with anthracycline-containing chemotherapy from 4 Korean institutions were included. RESULTS: Thirty-six patients (30.5%) had a low absolute lymphocyte count (ALC, < 1.0 × 109/L) at diagnosis. Patients with lymphopenia had shorter overall survival (OS) and progression-free survival (PFS) rates compared with patients with high ALCs (P = 0.003, P = 0.012, respectively). In multivariate analysis, high-intermediate/high-risk International Prognostic Index (IPI) scores and lymphopenia were both associated with shorter OS and PFS. Treatment-related mortality was 25.0% in the low ALC group and 4.8% in the high ALC group (P = 0.003). In patients considered high-intermediate/high-risk based on IPI scores, lymphopenia was also associated with shorter OS and PFS (P = 0.002, P = 0.001, respectively). CONCLUSION: This study suggests that lymphopenia could be an independent prognostic marker to predict unfavorable OS and PFS in patients with PTCL-NOS treated with anthracycline-containing chemotherapy and can be used to further stratify high-risk patients using IPI scores.-
dc.description.statementOfResponsibilityopen-
dc.format.extent34-
dc.relation.isPartOfJOURNAL OF HEMATOLOGY & ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAnthracyclines/therapeutic use*-
dc.subject.MESHAntineoplastic Agents/therapeutic use*-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHLymphocyte Count-
dc.subject.MESHLymphoma, T-Cell, Peripheral/complications-
dc.subject.MESHLymphoma, T-Cell, Peripheral/diagnosis*-
dc.subject.MESHLymphoma, T-Cell, Peripheral/drug therapy*-
dc.subject.MESHLymphopenia/complications*-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPrognosis-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHYoung Adult-
dc.titleLymphopenia is an important prognostic factor in peripheral T-cell lymphoma (NOS) treated with anthracycline-containing chemotherapy.-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorYu Ri Kim-
dc.contributor.googleauthorJin Seok Kim-
dc.contributor.googleauthorSoo Jeong Kim-
dc.contributor.googleauthorHyun Ae Jung-
dc.contributor.googleauthorSeok Jin Kim-
dc.contributor.googleauthorWon Seog Kim-
dc.contributor.googleauthorHye Won Lee-
dc.contributor.googleauthorHyeon Seok Eom-
dc.contributor.googleauthorSeong Hyun Jeong-
dc.contributor.googleauthorJoon Seong Park-
dc.contributor.googleauthorJune-Won Cheong-
dc.contributor.googleauthorYoo Hong Min-
dc.identifier.doi10.1186/1756-8722-4-34-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA00633-
dc.contributor.localIdA03729-
dc.contributor.localIdA01017-
dc.contributor.localIdA01407-
dc.contributor.localIdA00779-
dc.relation.journalcodeJ01439-
dc.identifier.eissn1756-8722-
dc.identifier.pmid21843362-
dc.subject.keywordperipheral T-cell lymphoma-
dc.subject.keywordnot otherwise specified-
dc.subject.keywordlymphopenia-
dc.subject.keywordinternational prognostic index-
dc.subject.keywordprognostic factor-
dc.contributor.alternativeNameKim, Soo Jeong-
dc.contributor.alternativeNameCheong, June Won-
dc.contributor.alternativeNameKim, Yu Ri-
dc.contributor.alternativeNameKim, Jin Seok-
dc.contributor.alternativeNameMin, Yoo Hong-
dc.contributor.affiliatedAuthorKim, Soo Jeong-
dc.contributor.affiliatedAuthorCheong, June-Won-
dc.contributor.affiliatedAuthorKim, Jin Seok-
dc.contributor.affiliatedAuthorMin, Yoo Hong-
dc.contributor.affiliatedAuthorKim, Yu Ri-
dc.rights.accessRightsfree-
dc.citation.volume4-
dc.citation.startPage34-
dc.identifier.bibliographicCitationJOURNAL OF HEMATOLOGY & ONCOLOGY, Vol.4 : 34, 2011-
dc.identifier.rimsid28444-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.